Neoadjuvant nivolumab treatment in patients with glioblastoma induces intratumoral immune activation and underscores the need for rationale-based combination approaches for improving clinical responses.
- Kurt A. Schalper
- Maria E. Rodriguez-Ruiz
- Ignacio Melero